Clinical Trial Update: Study of KN026 Monotherapy or Combination Therapy in Patients With Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update of KN026 as monotherapy or in combination for metastatic breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• KN026

Snippet

Sponsor: Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Conditions: Metastatic Breast Cancer | Phase 2 | Status: UNKNOWN